2710 Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Mechanistic Studies to Investigate the 

Interrelationship Between Sleep and/or 

Circadian Rhythms and Substance Use 

Disorders. 

Date: February 21, 2025. 

Time: 10:00 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Ipolia R. Ramadan, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 827–4471, 

ramadanir@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Interplay of Autophagy Regulated Cell Death 

and HIV Pathogenesis in Substance Use 

Disorders and Research on the NeuroImmune Axis in the Context of HIV and 

Substance Use. 

Date: February 24, 2025. 

Time: 11:00 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Meysam Yazdankhah, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, National Institute on Drug 

Abuse, NIH, 301 North Stonestreet Avenue, 

MSC 6021, Bethesda, MD 20892, (301) 402– 

6965, meysam.yazdankhah@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: January 6, 2025. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2025–00455 Filed 1–10–25; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council for Human Genome Research. 

This is a video assisted meeting held 

virtually. It is open to the public as 

indicated below. Individuals who plan 

to view the virtual meeting and need 

special assistance or other reasonable 

accommodations, should notify the 

contact person listed below in advance 

of the meeting. The meeting will be 

videocast and can be accessed from 

https://www.genome.gov/eventcalendar/105th-Meeting-of-NationalAdvisory-Council-for-Human-GenomeResearch. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council for Human Genome Research. 

Date: February 10–11, 2025. 

Closed: February 10, 2025, 9:00 a.m. to 

10:00 a.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Human Genome 

Research Institute, National Institutes of 

Health, 6700B Rockledge Drive, Room 1100, 

Bethesda, MD 20892 (Virtual). 

Open: February 10, 2025, 10:00 a.m. to 6:00 

p.m. 

Agenda: Report of Institute Director and 

Institute Staff. 

Address: National Human Genome 

Research Institute, National Institutes of 

Health, 6700B Rockledge Drive, Room 1100, 

Bethesda, MD 20892 (Virtual). 

Closed: February 11, 2025, 11:00 a.m. to 

5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Human Genome 

Research Institute, National Institutes of 

Health, 6700B Rockledge Drive, Room 1100, 

Bethesda, MD 20892 (Virtual). 

Contact Person: Jennifer L. Troyer, Ph.D., 

Director, Division of Extramural Operations, 

National Human Genome Research Institute, 

National Institutes of Health, 5635 Fishers 

Lane, Suite 4076, Rockville, MD 20852, (301) 

480–3565, troyerj@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: http://

www.genome.gov/council, where an agenda 

and any additional information for the 

meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: January 6, 2025. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2025–00469 Filed 1–10–25; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS– 

2023–1 Phase II: Adaptation of CRISPR-Based 

In Vitro Diagnostics for Rapid Detection of 

Select Eukaryotic Pathogens (Topic 119). 

Date: February 4, 2025. 

Time: 1:00 p.m. to 4:00 p.m. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Rockville, MD 

20892 (Video Assisted Meeting). 

Agenda: To review and evaluate contract 

proposals. 

Contact Person: Mario Cerritelli, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 


ddrumheller on DSK120RN23PROD with NOTICES1